• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性血液透析患者血红蛋白变异性与死亡率之间关联的历史调整边际结构分析。

History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.

作者信息

Brunelli Steven M, Joffe Marshall M, Israni Rubeen K, Yang Wei, Fishbane Steven, Berns Jeffrey S, Feldman Harold I

机构信息

Renal, Electrolyte and Hypertension Division of the Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

出版信息

Clin J Am Soc Nephrol. 2008 May;3(3):777-82. doi: 10.2215/CJN.04281007. Epub 2008 Mar 12.

DOI:10.2215/CJN.04281007
PMID:18337553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2386696/
Abstract

BACKGROUND AND OBJECTIVES

Hemoglobin variability is common among dialysis patients, and has been associated with increased mortality. The causal nature of this association has been difficult to ascertain because of potential time-dependent confounding, for which traditional statistical methods do not control.

DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: A retrospective cohort of 34,963 Fresenius Medical care dialysis patients from 1996 was assembled. Hemoglobin variability, absolute hemoglobin level, and temporal hemoglobin trend were measured over rolling 6-mo exposure windows. Their association with mortality was estimated using history-adjusted marginal structural analysis that adjusts for time-dependent confounding by applying weights to observations inversely related to the predictability of observed levels of hemoglobin.

RESULTS

In the primary analysis, each g/dl increase in hemoglobin variability was associated with an adjusted hazard ratio (HR) [95% confidence interval (CI)] for all-cause mortality of 1.93 (1.20 to 3.10). Neither higher absolute hemoglobin level nor increasing hemoglobin trend were significantly associated with mortality; adjusted HR (95% CI) 0.85 (0.64 to 1.11) and 0.60 (0.25 to 1.45), respectively.

CONCLUSIONS

Marginal structural analysis demonstrates that hemoglobin variability is associated with increased mortality among chronic hemodialysis patients, and that this effect is more pronounced than appreciated using standard statistical techniques that do not take time-dependent confounding into account.

摘要

背景与目的

血红蛋白变异性在透析患者中很常见,且与死亡率增加有关。由于存在潜在的时间依赖性混杂因素,这种关联的因果性质难以确定,而传统统计方法无法控制此类因素。

设计、地点、参与者及测量方法:收集了1996年以来34963例费森尤斯医疗护理透析患者的回顾性队列。在滚动的6个月暴露窗口期间测量血红蛋白变异性、绝对血红蛋白水平和血红蛋白时间趋势。使用历史调整的边际结构分析估计它们与死亡率的关联,该分析通过对与观察到的血红蛋白水平可预测性呈负相关的观察值应用权重来调整时间依赖性混杂因素。

结果

在初步分析中,血红蛋白变异性每增加1g/dl,全因死亡率的调整后风险比(HR)[95%置信区间(CI)]为1.93(1.20至3.10)。较高的绝对血红蛋白水平和上升的血红蛋白趋势均与死亡率无显著关联;调整后HR(95%CI)分别为0.85(0.64至1.11)和0.60(0.25至1.45)。

结论

边际结构分析表明,血红蛋白变异性与慢性血液透析患者死亡率增加有关,且这种影响比未考虑时间依赖性混杂因素的标准统计技术所显示的更为明显。

相似文献

1
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.慢性血液透析患者血红蛋白变异性与死亡率之间关联的历史调整边际结构分析。
Clin J Am Soc Nephrol. 2008 May;3(3):777-82. doi: 10.2215/CJN.04281007. Epub 2008 Mar 12.
2
Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients.当代新发病血液透析患者血红蛋白变异性与死亡率的关联
Clin J Am Soc Nephrol. 2008 Nov;3(6):1733-40. doi: 10.2215/CJN.02390508. Epub 2008 Oct 15.
3
Hemoglobin level variability: associations with mortality.血红蛋白水平变异性:与死亡率的关联。
Clin J Am Soc Nephrol. 2008 Jan;3(1):133-8. doi: 10.2215/CJN.01610407. Epub 2007 Nov 28.
4
Association of hemoglobin and survival in peritoneal dialysis patients.血红蛋白与腹膜透析患者生存的关系。
Clin J Am Soc Nephrol. 2011 Aug;6(8):1973-81. doi: 10.2215/CJN.01050211. Epub 2011 Jul 22.
5
Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.促红细胞生成素剂量对美国老年血液透析患者生存率的估计影响。
Clin J Am Soc Nephrol. 2009 Mar;4(3):638-44. doi: 10.2215/CJN.05071008. Epub 2009 Mar 4.
6
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.在一家大型非营利性透析机构中,贫血管理以及种族与死亡率和住院率的关联
Am J Kidney Dis. 2009 Sep;54(3):498-510. doi: 10.1053/j.ajkd.2009.05.007. Epub 2009 Jul 23.
7
Association between post-dialysis hemoglobin level and the survival of vascular access.透析后血红蛋白水平与血管通路存活之间的关联
J Vasc Access. 2018 Jan;19(1):69-75. doi: 10.5301/jva.5000798.
8
Relationship between epoetin alfa dose and mortality: findings from a marginal structural model.促红细胞生成素阿尔法剂量与死亡率的关系:来自边缘结构模型的研究结果。
Clin J Am Soc Nephrol. 2010 Feb;5(2):182-8. doi: 10.2215/CJN.03040509. Epub 2009 Dec 17.
9
The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.较高血红蛋白水平对血液透析患者死亡率和住院率的影响。
Kidney Int. 2003 May;63(5):1908-14. doi: 10.1046/j.1523-1755.2003.00937.x.
10
Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.在一项针对医疗保险血液透析患者的回顾性队列研究中,平均每周促红细胞生成素α剂量与死亡风险的关系。
Am J Nephrol. 2011;34(4):298-308. doi: 10.1159/000330693. Epub 2011 Aug 9.

引用本文的文献

1
Associations between serum potassium variability and mortality in patients undergoing maintenance hemodialysis: a retrospective study.维持性血液透析患者血清钾变异性与死亡率的相关性:一项回顾性研究。
Sci Rep. 2024 Dec 2;14(1):29998. doi: 10.1038/s41598-024-80709-3.
2
Automated Dialysis Anemia Management: Role of the Treating Nephrologist.自动化透析贫血管理:主治肾病专家的作用。
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1084-1085. doi: 10.2215/CJN.0000000000000541. Epub 2024 Aug 13.
3
Effects of Individualized Anemia Therapy on Hemoglobin Stability: A Randomized Controlled Pilot Trial in Patients on Hemodialysis.个体化贫血治疗对血红蛋白稳定性的影响:一项针对血液透析患者的随机对照试验
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1138-1147. doi: 10.2215/CJN.0000000000000488. Epub 2024 Jun 11.
4
Infectious Risk and Variability of Hemoglobin Level in Patients Undergoing Hemodialysis.接受血液透析患者的感染风险及血红蛋白水平的变异性
Kidney Int Rep. 2023 Jun 14;8(9):1752-1760. doi: 10.1016/j.ekir.2023.06.004. eCollection 2023 Sep.
5
Initiation of renin-angiotensin system inhibitors and first complete remission in patients with primary nephrotic syndrome: a nationwide cohort study.肾素-血管紧张素系统抑制剂的起始使用与原发性肾病综合征患者的首次完全缓解:一项全国性队列研究
Clin Exp Nephrol. 2023 May;27(5):480-489. doi: 10.1007/s10157-023-02331-3. Epub 2023 Feb 25.
6
Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study.贫血生物标志物与合并或不合并糖尿病的血液透析患者的死亡率:一项 10 年随访研究。
PLoS One. 2023 Jan 31;18(1):e0280871. doi: 10.1371/journal.pone.0280871. eCollection 2023.
7
The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review.慢性肾脏病贫血对患者的影响:发病率、危险因素及临床结局——一项系统文献综述
Int J Nephrol. 2020 Jul 1;2020:7692376. doi: 10.1155/2020/7692376. eCollection 2020.
8
Estimation of homeostatic dysregulation and frailty using biomarker variability: a principal component analysis of hemodialysis patients.使用生物标志物变异性评估体内平衡失调和虚弱:血液透析患者的主成分分析。
Sci Rep. 2020 Jun 25;10(1):10314. doi: 10.1038/s41598-020-66861-6.
9
The Influence of Inflammation on Anemia in CKD Patients.炎症对慢性肾脏病患者贫血的影响。
Int J Mol Sci. 2020 Jan 22;21(3):725. doi: 10.3390/ijms21030725.
10
Haemoglobin variability and all-cause mortality in haemodialysis patients: A systematic review and meta-analysis.血红蛋白变异性与血液透析患者全因死亡率:系统评价和荟萃分析。
Nephrology (Carlton). 2019 Dec;24(12):1265-1272. doi: 10.1111/nep.13560. Epub 2019 Feb 28.

本文引用的文献

1
Causal inference in longitudinal studies with history-restricted marginal structural models.使用历史受限边际结构模型的纵向研究中的因果推断
Electron J Stat. 2007 Jan 1;1:119-154. doi: 10.1214/07-EJS050.
2
Hemoglobin variability and mortality in ESRD.终末期肾病患者血红蛋白变异性与死亡率
J Am Soc Nephrol. 2007 Dec;18(12):3164-70. doi: 10.1681/ASN.2007010058. Epub 2007 Nov 14.
3
Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003.1998年至2003年期间,静脉注射左卡尼汀对维持性血液透析患者次月住院率的保护作用。
Am J Kidney Dis. 2007 Nov;50(5):803-12. doi: 10.1053/j.ajkd.2007.07.017.
4
Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.血红蛋白水平变异性:与合并症、并发事件及住院治疗的关联
Clin J Am Soc Nephrol. 2006 Nov;1(6):1205-10. doi: 10.2215/CJN.01110306. Epub 2006 Sep 6.
5
Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.血红蛋白变化与促红细胞生成素给药及血液透析患者生存率之间的关联。
J Am Soc Nephrol. 2006 Apr;17(4):1181-91. doi: 10.1681/ASN.2005090997.
6
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.接受重组人促红细胞生成素治疗的血液透析患者的血红蛋白循环
Kidney Int. 2005 Sep;68(3):1337-43. doi: 10.1111/j.1523-1755.2005.00532.x.
7
Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.对无症状性心脏病的初诊血液透析患者进行完全和部分贫血纠正的双盲比较。
J Am Soc Nephrol. 2005 Jul;16(7):2180-9. doi: 10.1681/ASN.2004121039. Epub 2005 May 18.
8
Activated injectable vitamin D and hemodialysis survival: a historical cohort study.活性注射用维生素D与血液透析生存率:一项历史性队列研究。
J Am Soc Nephrol. 2005 Apr;16(4):1115-25. doi: 10.1681/ASN.2004070573. Epub 2005 Feb 23.
9
Administration of parenteral iron and mortality among hemodialysis patients.胃肠外铁剂给药与血液透析患者的死亡率
J Am Soc Nephrol. 2004 Jun;15(6):1623-32. doi: 10.1097/01.asn.0000128009.69594.be.
10
Hemoglobin variability in epoetin-treated hemodialysis patients.促红细胞生成素治疗的血液透析患者的血红蛋白变异性
Kidney Int. 2003 Oct;64(4):1514-21. doi: 10.1046/j.1523-1755.2003.00229.x.